Logo of Noxopharm (ASX:NOX)Latest Noxopharm (ASX:NOX) News

Page 1
Page 1 of 4

Market Wrap - Week 45 (2 Nov -> 6 Nov) 2026

NEXTDC, Vintage Energy and Embelton recorded the week’s biggest moves, but each came with a different reason and level of risk.
Across resources, takeovers and healthcare, investors rewarded firm deals while selling companies that still need cash or approvals.
Logan Eniac
7 Nov 2026

Healthcare Wrap - Week 45 (2 Nov -> 6 Nov) 2026

Healthcare shares delivered a mixed week as investors rewarded reimbursement and regulatory progress but punished cash calls and dilution. Noxopharm, Pacific Edge and Mayne Pharma led the largest moves, while several companies still face long waits before sales can grow.
Logan Eniac
7 Nov 2026

Noxopharm secures funding bridge as lupus trial moves towards patients

Noxopharm has secured a $1.5 million placement and agreed to convert $3.78 million of shareholder notes as it prepares to test SOF-SKN in cutaneous lupus patients. The funding eases an immediate cash constraint, but the package also brings substantial dilution and remains partly subject to shareholder approval.
Ada Torres
2 Nov 2026

Healthcare Wrap - Week 44 (26 Oct -> 30 Oct) 2026

Healthcare shares split between clinical progress and cash pressure this week. Mesoblast rose on stronger Ryoncil sales, while several small biotechnology companies fell as investors weighed funding needs and delayed milestones.
Logan Eniac
31 Oct 2026

Noxopharm suspends trading ahead of capital raising announcement

Noxopharm has halted trading in its securities while it prepares an announcement about a capital raising. The suspension is scheduled to last until the earlier of the announcement or the start of trading on 2 November 2026, unless ASX decides otherwise.
Ada Torres
29 Oct 2026

Healthcare Wrap - Week 42 (12 Oct -> 16 Oct) 2026

Healthcare shares swung between sharp selling and early commercial progress this week, with EBR Systems falling 40.43% while Firebrick rose 13.79%.
Sales growth, clinical decisions and limited cash reserves remained the key tests for small healthcare companies.
Logan Eniac
17 Oct 2026

Noxopharm’s clinical progress meets a sharp funding test

Noxopharm has completed its first-in-human safety trial for SOF-SKN and advanced the wider Sofra platform, but its annual report flags a material uncertainty over funding. The biotech ended June with A$293,573 in cash, net liabilities of A$3.65 million and a need for additional capital.
Ada Torres
16 Oct 2026

Healthcare Wrap - Week 41 (5 Oct -> 9 Oct) 2026

Cynata led the week after launching a small capital raising, while Vitasora and Neurizon posted strong gains despite very different risks. Across healthcare, trial progress and regulator feedback competed with cash warnings and weaker share prices after trading gaps.
Logan Eniac
10 Oct 2026

Noxopharm gets FDA backing for SOF-SKN Phase II pathway

Noxopharm says the FDA has supported its proposed Phase II design and chemical manufacturing strategy for SOF-SKN, its topical treatment candidate for cutaneous lupus erythematosus. The feedback improves regulatory clarity, but the trial remains targeted for the first half of calendar 2028 and is subject to further studies and regulatory requirements.
Ada Torres
8 Oct 2026

Healthcare Wrap - Week 30 (20 July -> 24 July) 2026

Lumos led healthcare stocks higher after widening its US urgent care rollout, while Tissue Repair tumbled on its plan to leave the ASX. Strong trial updates, FDA steps and fresh funding kept the sector busy, even as several stocks fell despite good news.
Logan Eniac
25 July 2026

Noxopharm Advances Sofra Platform with Cancer Data and FDA Trial Prep

Noxopharm reported significant progress in its Sofra technology, highlighting enhanced cancer drug potential and preparations for a US FDA clinical trial, while managing tight cash reserves.
Ada Torres
22 July 2026

Healthcare Wrap - Week 28 (6 July -> 10 July) 2026

Healthcare stocks swung hard this week as debt clean-ups, fresh funding and product sales updates drove the biggest moves. The strongest gains came from companies with clear near-term cash or commercial news, while some early spikes faded once trading settled.
Logan Eniac
11 July 2026